ZIOPHARM Oncology, Inc. (ZIOP) Posts Narrower than Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Financial Fact:
Research contract revenue: 1.6M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Research contract revenue: 1.6M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) reported Q4 EPS of ($0.24), $0.05 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $170 thousand.
For earnings history and earnings-related data on ZIOPHARM Oncology, Inc. (ZIOP) click here.
For earnings history and earnings-related data on ZIOPHARM Oncology, Inc. (ZIOP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Red River Bancshares, Inc. (RRBI) Tops Q3 EPS by 7c
- Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Third Quarter Ended September 30, 2026 Financial Results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
